Extended Follow-Up May Elucidate How ctDNA Impacts RMC-6236 PDAC Outcomes
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Related Articles
Prostate cancer spit test could save the NHS £500 million a year
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new…
Association of opioid use with survival in patients with cancer treated with immune checkpoint inhibitors: it is time for evidence-based behaviors
A recent review suggested that the use of opioids during immune checkpoint inhibitor (ICI) treatment has an adverse effect on patient prognosis. This artic
Regulatory Fate of Cancer Indications in the EU After Accelerated Approval in the US
This cohort study investigates the regulatory fate in the European Union for drugs that received accelerated approval for cancer indications in the US.
Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC
Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.
Programme | EAHAD 2025
View the programme for an outline of the engaging topics being presented at EAHAD 2025.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
United by Unique: A call for people‐centred cancer care on World Cancer Day 2025
Click on the article title to read more.
Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer
Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
In this Article of the Month podcast Annals of Oncology Editor-in-Chief Tom Powles discusses with Dr Laurence Albiges, of Department of Oncology, Institut Gustave Roussy,…
